Hydroxyethyl starch (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hydroxyethyl starch" in English language version.

refsWebsite

Global rank English rank

15nih.gov

4^th place

12doi.org

2^nd place

5europa.eu

68^th place

117^th place

5semanticscholar.org

11^th place

8^th place

4web.archive.org

1^st place

4fda.gov

447^th place

338^th place

2federalregister.gov

2,474^th place

1,469^th place

1oxfordjournals.org

1,389^th place

2,996^th place

1sciencenordic.com

low place

1mhra.gov.uk

low place

doi.org

Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. (February 2013). "Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis". JAMA. 309 (7): 678–688. doi:10.1001/jama.2013.430. PMID 23423413.
Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H (July 2009). "Hydroxyethyl starches: different products--different effects". Anesthesiology. 111 (1): 187–202. doi:10.1097/aln.0b013e3181a7ec82. PMID 19512862.
Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. (August 2018). "Colloids versus crystalloids for fluid resuscitation in critically ill people". The Cochrane Database of Systematic Reviews. 8 (8): CD000567. doi:10.1002/14651858.CD000567.pub7. PMC 6513027. PMID 30073665.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. (January 2008). "Intensive insulin therapy and pentastarch resuscitation in severe sepsis". The New England Journal of Medicine. 358 (2): 125–139. doi:10.1056/NEJMoa070716. PMID 18184958. S2CID 8441982.
Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, et al. (January 2011). "Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial". Trials. 12: 24. doi:10.1186/1745-6215-12-24. PMC 3040153. PMID 21269526.
Downar J, Lapinsky SE (29 January 2009). "Pro/con debate: should synthetic colloids be used in patients with septic shock?". Critical Care. 13 (1): 203. doi:10.1186/cc7147. PMC 2688101. PMID 19226441.
Antonelli M, Sandroni C (February 2013). "Hydroxyethyl starch for intravenous volume replacement: more harm than benefit". JAMA. 309 (7): 723–724. doi:10.1001/jama.2013.851. PMID 23423420.
Hartog C, Reinhart K (August 2009). "CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients". Intensive Care Medicine. 35 (8): 1337–1342. doi:10.1007/s00134-009-1521-5. PMID 19533093. S2CID 7973629.
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. (July 2012). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–134. doi:10.1056/NEJMoa1204242. PMID 22738085. S2CID 5893988.
Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. (November 2012). "Hydroxyethyl starch or saline for fluid resuscitation in intensive care". The New England Journal of Medicine. 367 (20): 1901–1911. doi:10.1056/NEJMoa1209759. PMID 23075127.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (February 2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Critical Care Medicine. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. S2CID 34855187.
Bork K (January 2005). "Pruritus precipitated by hydroxyethyl starch: a review". The British Journal of Dermatology. 152 (1): 3–12. doi:10.1111/j.1365-2133.2004.06272.x. PMID 15656795. S2CID 13483776.

europa.eu

ema.europa.eu

"Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients" (Press release). European Medicines Agency. 23 October 2013.
"European Medicines Agency - Human medicines - Hydroxyethyl starch (HES) containing medicinal products". www.ema.europa.eu. Archived from the original on 28 January 2018. Retrieved 27 January 2018.
"Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients". European Medicines Agency. 17 July 2018.
"Hydroxyethyl-starch solutions for infusion recommended for suspension from the market | European Medicines Agency". 24 February 2022. Retrieved 11 June 2022.
"PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients" (Press release). Pharmacovigilance Risk Assessment Committee, European Medicines Agency. 11 October 2013. Archived from the original on 30 July 2018. Retrieved 11 October 2013.

fda.gov

"Public Workshop: Risks and Benefits of Hydroxyethyl Starch Solutions", Vaccines, Blood & Biologics, U.S. Food and Drug Administration
"FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings", Vaccines, Blood & Biologics, U.S. Food and Drug Administration, 25 November 2013
"Labeling Changes on mortality, kidney injury, and excess bleeding with hydroxyethyl starch products". FDA. October 2021. Retrieved 22 February 2023.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

federalregister.gov

"Federal Register". FDA. 9 December 2021. Retrieved 22 February 2023.
"Federal Register". FDA. 22 September 2021. Retrieved 22 February 2023.

mhra.gov.uk

Press release: MHRA suspends use of hydroxyethyl starch (HES) drips, Medicines and Healthcare products Regulatory Agency, 27 June 2013, archived from the original on 1 July 2013

nih.gov

pubmed.ncbi.nlm.nih.gov

Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. (February 2013). "Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis". JAMA. 309 (7): 678–688. doi:10.1001/jama.2013.430. PMID 23423413.
Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H (July 2009). "Hydroxyethyl starches: different products--different effects". Anesthesiology. 111 (1): 187–202. doi:10.1097/aln.0b013e3181a7ec82. PMID 19512862.
Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. (August 2018). "Colloids versus crystalloids for fluid resuscitation in critically ill people". The Cochrane Database of Systematic Reviews. 8 (8): CD000567. doi:10.1002/14651858.CD000567.pub7. PMC 6513027. PMID 30073665.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. (January 2008). "Intensive insulin therapy and pentastarch resuscitation in severe sepsis". The New England Journal of Medicine. 358 (2): 125–139. doi:10.1056/NEJMoa070716. PMID 18184958. S2CID 8441982.
Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, et al. (January 2011). "Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial". Trials. 12: 24. doi:10.1186/1745-6215-12-24. PMC 3040153. PMID 21269526.
Downar J, Lapinsky SE (29 January 2009). "Pro/con debate: should synthetic colloids be used in patients with septic shock?". Critical Care. 13 (1): 203. doi:10.1186/cc7147. PMC 2688101. PMID 19226441.
Antonelli M, Sandroni C (February 2013). "Hydroxyethyl starch for intravenous volume replacement: more harm than benefit". JAMA. 309 (7): 723–724. doi:10.1001/jama.2013.851. PMID 23423420.
Hartog C, Reinhart K (August 2009). "CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients". Intensive Care Medicine. 35 (8): 1337–1342. doi:10.1007/s00134-009-1521-5. PMID 19533093. S2CID 7973629.
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. (July 2012). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–134. doi:10.1056/NEJMoa1204242. PMID 22738085. S2CID 5893988.
Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. (November 2012). "Hydroxyethyl starch or saline for fluid resuscitation in intensive care". The New England Journal of Medicine. 367 (20): 1901–1911. doi:10.1056/NEJMoa1209759. PMID 23075127.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (February 2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Critical Care Medicine. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. S2CID 34855187.
Bork K (January 2005). "Pruritus precipitated by hydroxyethyl starch: a review". The British Journal of Dermatology. 152 (1): 3–12. doi:10.1111/j.1365-2133.2004.06272.x. PMID 15656795. S2CID 13483776.

ncbi.nlm.nih.gov

Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. (August 2018). "Colloids versus crystalloids for fluid resuscitation in critically ill people". The Cochrane Database of Systematic Reviews. 8 (8): CD000567. doi:10.1002/14651858.CD000567.pub7. PMC 6513027. PMID 30073665.
Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, et al. (January 2011). "Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial". Trials. 12: 24. doi:10.1186/1745-6215-12-24. PMC 3040153. PMID 21269526.
Downar J, Lapinsky SE (29 January 2009). "Pro/con debate: should synthetic colloids be used in patients with septic shock?". Critical Care. 13 (1): 203. doi:10.1186/cc7147. PMC 2688101. PMID 19226441.

oxfordjournals.org

"Editors-in-Chief Statement Regarding Published Clinical Trials Conducted without IRB Approval by Joachim Boldt" (PDF), Oxford Journals, 4 March 2011, archived from the original (PDF) on 21 March 2011

sciencenordic.com

Wojcik J (24 July 2012). "Pharma giant threatens Danish scientist". ScienceNordic. Retrieved 13 August 2012.

semanticscholar.org

api.semanticscholar.org

Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. (January 2008). "Intensive insulin therapy and pentastarch resuscitation in severe sepsis". The New England Journal of Medicine. 358 (2): 125–139. doi:10.1056/NEJMoa070716. PMID 18184958. S2CID 8441982.
Hartog C, Reinhart K (August 2009). "CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients". Intensive Care Medicine. 35 (8): 1337–1342. doi:10.1007/s00134-009-1521-5. PMID 19533093. S2CID 7973629.
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. (July 2012). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–134. doi:10.1056/NEJMoa1204242. PMID 22738085. S2CID 5893988.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (February 2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Critical Care Medicine. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. S2CID 34855187.
Bork K (January 2005). "Pruritus precipitated by hydroxyethyl starch: a review". The British Journal of Dermatology. 152 (1): 3–12. doi:10.1111/j.1365-2133.2004.06272.x. PMID 15656795. S2CID 13483776.

web.archive.org

"Editors-in-Chief Statement Regarding Published Clinical Trials Conducted without IRB Approval by Joachim Boldt" (PDF), Oxford Journals, 4 March 2011, archived from the original (PDF) on 21 March 2011
Press release: MHRA suspends use of hydroxyethyl starch (HES) drips, Medicines and Healthcare products Regulatory Agency, 27 June 2013, archived from the original on 1 July 2013
"European Medicines Agency - Human medicines - Hydroxyethyl starch (HES) containing medicinal products". www.ema.europa.eu. Archived from the original on 28 January 2018. Retrieved 27 January 2018.
"PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients" (Press release). Pharmacovigilance Risk Assessment Committee, European Medicines Agency. 11 October 2013. Archived from the original on 30 July 2018. Retrieved 11 October 2013.